Get startedLog in
    Picture of Recordati Industria Chimica E Farmaceutica SpA logo

    REC — Recordati Industria Chimica E Farmaceutica SpA News Story

    0.000.00%
    it flag iconLast trade - 00:00
    HealthcareConservativeLarge CapHigh Flyer
    All News

    Brief: Recordati Signs Exclusive Licensing & Supply Agreement With Amarin To Commercialize Vazkepa In Europe

    Picture of Recordati Industria Chimica E Farmaceutica SpA logoRecordati Industria Chimica E Farmaceutica SpA
    24/06/2025 12:09
    June 24 (Reuters) - Recordati Industria Chimica e Farmaceutica SpA RECI.MI:

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA IN EUROPE

RECORDATI TO PAY AMARIN AN UPFRONT CASH PAYMENT OF US$ 25 MILLION

AMARIN TO SUPPLY FINISHED PRODUCT TO RECORDATI, IS ELIGIBLE TO RECEIVE ROYALTIES FOR SUPPLY OF PRODUCT UNDER TERMS OF AGREEMENT, COMMERCIAL MILESTONES UP TO TOTAL OF US$ 150 MILLION IF ANNUAL REVENUES FOR VAZKEPA® IN TERRITORIES IN SCOPE EXCEED CERTAIN SALES THRESHOLDS STARTING FROM € 100 MILLION

MORE DETAILS TO BE PROVIDED ON JULY 30

Further company coverage: RECI.MI

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48587696600;))

    Recent news on Recordati Industria Chimica E Farmaceutica SpA

    See all news